Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-11-02 Share Issue/Capital Cha…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA - New share capital registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that a 'New share capital registered' following a 'successful placing of a private placement'. It details the resulting share capital amount and the number of shares. This directly relates to a change in the company's capital structure due to fundraising/share issuance. This aligns best with the 'Capital/Financing Update' (CAP) definition, as it confirms the finalization of a capital raise. Although 'Share Issue/Capital Change' (SHA) is also relevant, CAP is often used for the announcement of the successful completion of a financing round, which this document confirms by stating the registration with the Register of Business Enterprises.
2021-11-02 English
Ultimovacs ASA - Transactions by primary insiders and closely associated parties
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving shares of Ultimovacs ASA. Key phrases include 'Details of the person discharging managerial responsibilities/person closely associated', 'Position/status: Closely associated party of Henrik Schüssler, board member of the issuer', and 'Nature of the transaction: Subscription of shares in private placement'. This format is characteristic of mandatory regulatory filings disclosing insider or closely associated party transactions, specifically director's dealings or insider trading reports, which are often reported on specific forms depending on the jurisdiction (e.g., Form 3, 4, 5 in the US, or similar notifications in Europe). Among the provided codes, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for reports of personal share transactions by company directors and executives or their closely associated parties.
2021-10-27 English
Ultimovacs ASA - Transactions by primary insiders and closely associated parties
Director's Dealing Classification · 98% confidence The document explicitly details 'Transactions by primary insiders and closely associated parties' of Ultimovacs ASA, specifically listing allocations of 'Offer Shares' from a recent Private Placement to various board members and their associated entities. This content directly matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The filing type code for this is DIRS.
2021-10-27 English
Ultimovacs ASA - Private placement of new shares successfully placed
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the successful placement of a 'Private placement of new shares' by Ultimovacs ASA, detailing the gross proceeds (NOK 270 million), the subscription price, and the intended use of proceeds (financing clinical trials and general corporate purposes). This activity directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). Although it involves shares, it is a financing event announcement, not a general share issue/capital change (SHA) or a share repurchase (POS). It is a specific financing announcement, making CAP the most appropriate classification.
2021-10-26 English
Ultimovacs ASA - Contemplated private placement
Capital/Financing Update Classification · 99% confidence The document is an announcement titled "Ultimovacs ASA - Contemplated private placement". It details the intention to carry out a private placement to raise capital (NOK 225 to 270 million) by issuing new shares. This activity directly relates to fundraising, financing activities, and changes in capital structure. Based on the provided definitions, this aligns perfectly with the 'Capital/Financing Update' category.
2021-10-26 English
Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
Regulatory Filings Classification · 99% confidence The document is a press release dated October 26, 2021, announcing a clinical trial update: 'Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)'. It details the trial design, combination therapy (UV1 with pembrolizumab), expected timelines, and quotes management. This type of announcement, focusing on operational or clinical development news rather than mandatory financial reporting (like 10-K, ER, or IR), typically falls under general regulatory announcements or investor relations news. Since it is not a formal financial report, a proxy statement, or a specific transaction notice, the most appropriate general category for a significant operational update released via stock exchange is 'Regulatory Filings' (RNS), as it is a disclosure subject to market abuse regulations mentioned at the end ('This information is considered to be inside information pursuant to the EU Market Abuse Regulation'). It is not an Earnings Release (ER) or an Interim Report (IR) as it focuses on clinical progress, not financial results.
2021-10-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.